View Filing Data

Label

Element

Value

Percentage for purchase stock and fair value of common stock

ETON_PercentageForPurchaseStockAndFairValueOfCommonStock

85.00%

Unaudited Interim Financial Information

ETON_UnauditedInterimFinancialInformationPolicyTextBlock

Unaudited Interim Financial Information

The accompanying interim condensed financial statements are unaudited and have been prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments necessary for the fair presentation of the Company’s financial position as of March 31, 2020 and the results of its operations and its cash flows for the periods ended March 31, 2020 and 2019. The financial data and other information disclosed in these notes related to the three-month periods ended March 31, 2020 and 2019 are also unaudited. The results for the three-month period ended March 31, 2020 are not necessarily indicative of results to be expected for the year ending December 31, 2020, any other interim periods or any future year or period.

Percentage for total number of shares outstanding

ETON_PercentageForTotalNumberOfSharesOutstanding

4.00%

DebtOfInterestAmount

ETON_DebtOfInterestAmount

$ 2,667,000

Common stock issued for product candidate licensing rights

ETON_IssuanceOfStockForProductCandidateLicensingRights

1,264,000

Common stock issued for product candidate licensing rights

ETON_IssuanceOfStockForProductCandidateLicensingRights

Credit agreement term

ETON_CreditAgreementTerm

10 years

Credit agreement term

ETON_CreditAgreementTerm

5 years

Credit agreement term

ETON_CreditAgreementTerm

10 years

Credit agreement term

ETON_CreditAgreementTerm

10 years

Credit agreement term

ETON_CreditAgreementTerm

10 years

Credit agreement term

ETON_CreditAgreementTerm

10 years

LongTermDebtRepaymentsOfPrincipalAmount

ETON_LongTermDebtRepaymentsOfPrincipalAmount

$ 7,667,000

Weighted Average Remaining Contractual Term, Options Outstanding, Ending Balance

ETON_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3

8 years 6 months

Percentage of right to recoup

ETON_PercentageOfRightToRecoup

60.00%

Percentage of right to recoup

ETON_PercentageOfRightToRecoup

35.00%

Percentage of net profits payments to third party from sale of product

ETON_PercentageOfNetProfitsPaymentsToThirdPartyFromSaleOfProduct

50.00%

Percentage of net profits payments to third party from sale of product

ETON_PercentageOfNetProfitsPaymentsToThirdPartyFromSaleOfProduct

35.00%

Percentage of net profits payments to third party from sale of product

ETON_PercentageOfNetProfitsPaymentsToThirdPartyFromSaleOfProduct

35.00%

Percentage for additional profit

ETON_PercentageForAdditionalProfit

50.00%

Percentage for additional profit

ETON_PercentageForAdditionalProfit

50.00%

Percentage for additional profit

ETON_PercentageForAdditionalProfit

50.00%

Percentage for additional profit

ETON_PercentageForAdditionalProfit

50.00%

Common Stock Warrants

ETON_CommonStockWarrantsTextBlock

Note 7 — Common Stock Warrants

The Company’s outstanding warrants to purchase shares of its common stock at March 31, 2020 are summarized in the table below.

Description of Warrants	No. of Shares		Exercise Price
Business Advisory Warrants		600,000	$	0.01
Placement Agent Warrants – 2017 Preferred Stock Offering		607,096	$	3.00
Placement Agent Warrants - IPO		414,000	$	7.50
SWK Warrants - Debt		51,239	$	5.86
Total		1,672,335	$	3.13 (Avg)

The holders of these warrants or their permitted transferees, are entitled to rights with respect to the registration under the Securities Act of 1933, as amended (the “Securities Act”) for their shares that are converted to common stock, including demand registration rights and piggyback registration rights. These rights are provided under the terms of a registration rights agreement between the Company and the investors.

Product licensing rights amortized, description

ETON_ProductLicensingRightsAmortizedDescription

Cost is being amortized over five years.

Schedule of Lease-related Assets and Liabilities

ETON_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock

The table below presents the lease-related assets and liabilities recorded on the balance sheet as of March 31, 2020 (in thousands).

Assets	Classification
Operating lease right-of-use assets	Operating lease right-of-use assets, net	$	129
Total leased assets		$	129
Liabilities
Operating lease liabilities, current	Accrued liabilities	$	120
Total operating lease liabilities		$	120

Percentage of net sales as marketing fees

ETON_PercentageOfNetSalesAsMarketingFees

5.00%

Percentage of net sales as marketing fees

ETON_PercentageOfNetSalesAsMarketingFees

5.00%

Amortization rights to use of assets

ETON_OperatingLeaseRightOfUseAssetAmortization

$ 31,000

Amortization rights to use of assets

ETON_OperatingLeaseRightOfUseAssetAmortization

$ 30,000

Description for deductions to purchase stock at price per share

ETON_DescriptionForDeductionsToPurchaseStockAtPricePerShare

The initial offering of the ESPP began on December 17, 2018 and ended on December 10, 2019. The annual offerings consist of two stock purchase periods, with the first purchase period ending in June and the second purchase period ending in December. The terms of the ESPP permit employees of the Company to use payroll deductions to purchase stock at a price per share that is at least the lesser of (1) 85% of the fair market value of a share of common stock on the first date of an offering or (2) 85% of the fair market value of a share of common stock on the date of purchase. After the initial offering period ended, subsequent twelve-month offering periods automatically commence over the term of the ESPP on the day that immediately follows the conclusion of the preceding offering, each consisting of two purchase periods approximately six months in duration.

Number of products

ETON_NumberOfProducts

Issuance of common stock for product candidate licensing rights

ETON_StockIssuedDuringPeriodValueForProductCandidateLicensingRights

$ 1,264,000

Issuance of common stock for product candidate licensing rights

ETON_StockIssuedDuringPeriodValueForProductCandidateLicensingRights

Issuance of common stock for product candidate licensing rights

ETON_StockIssuedDuringPeriodValueForProductCandidateLicensingRights

1,264,000

Issuance of common stock for product candidate licensing rights

ETON_StockIssuedDuringPeriodValueForProductCandidateLicensingRights

Number of outside directors

ETON_NumberOfDirectors

Issuance of common stock for product candidate licensing rights, shares

ETON_StockIssuedDuringPeriodSharesForProductCandidateLicensingRights

379,474

Minimum cash balance to be maintain in each quarter end

ETON_MinimumCashBalanceToBeMaintainInEachQuarterEnd

$ 3,000,000

Component of long term

ETON_ComponentOfLongtermDebt

3,000

Thereafter

ETON_LesseeOperatingLeaseLiabilityPaymentsDueThereafter

Diurnal Limited [Member]

Cash paid for licensing milestone fee

ETON_CashPaidForLicensingMilestoneFee

3,500,000

Aggregate value of licensing milestone amount included in research and development expense

ETON_AggregateValueOfLicensingMilestoneIncludedInResearchAndDevelopmentExpense

4,764,000

Aucta Pharmaceuticals, Inc [Member]

Milestone payment amount

ETON_MilestonePaymentAmount

18,000,000

Milestone payment amount

ETON_MilestonePaymentAmount

1,000,000

Milestone payment amount

ETON_MilestonePaymentAmount

2,000,000

Milestone payment amount

ETON_MilestonePaymentAmount

5,000,000

Milestone payment amount

ETON_MilestonePaymentAmount

$ 10,000,000

Milestone payment description

ETON_MilestonePaymentDescription

$1,000 when net sales exceed $10 million in a calendar year, $2,000 when net sales exceed $20 million in a calendar year, $5,000 when net sales exceed $50 million in a calendar year, $10,000 when net sales exceed $100 million in a calendar year

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2020	Apr. 30, 2020
Document And Entity Information
Entity Registrant Name	Eton Pharmaceuticals, Inc.
Entity Central Index Key	0001710340
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		20,917,028
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020

Print Document View Excel Document
Cover Document and Entity Information Uncategorized Uncategorized Items - eton-20200331.xml All Reports